secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001297184-24-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q1 2024 net revenue $171.8M, GAAP EPS $0.81, adjusted EPS $1.04
-------------------------------------------------------------------------

- Net revenues of $171.8M vs $140.0M in Q1 2023, up 23% YoY.
- GAAP net income $43.2M ($0.81 dil EPS) vs $26.0M ($0.50) a year ago.
- Adjusted non-GAAP net income $55.3M ($1.04 dil EPS) vs $32.1M ($0.62) YoY.
- BAQSIMI revenue grew 22% over Eli Lilly's reported Q1 2023 revenue.
- No forward guidance provided in the release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718424000033/0001297184-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718424000033/amph-20240508x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer